Abstract:Background D‐dimer is involved in poor outcomes of stroke as a coagulation biomarker. We aimed to investigate the associations of the level and increase in D‐dimer between baseline and 90 days with all‐cause death or poor functional outcome in patients after ischemic stroke or transient ischemic attack. Methods and Results We collected data from the CNSRIII (Third China National Stroke Registry) study. The present substudy included 10 518 patients within 7 days (baseline) of ischemic stroke or transient ischemic attack and 6268 patients at 90 days. Poor functional outcome at 1 year was assessed on the basis of the modified Rankin Scale (≥3). Multivariable Cox regression or logistic regression was used to assess the association of D‐dimer levels with all‐cause death or poor functional outcome. D‐dimer levels at 90 days were lower than those at baseline (1.4 μg/mL versus 1.7 μg/mL; P <0.001). Higher baseline D‐dimer level was associated with all‐cause death (adjusted hazard ratio [HR], 1.77; 95% CI, 1.25–2.52; P =0.001) and poor functional outcome (adjusted odds ratio [OR], 1.49; 95% CI, 1.23–1.80; P <0.001) during 1‐year follow‐up. Higher D‐dimer level at 90 days was also associated with poor outcomes independently. Furthermore, an increase in D‐dimer levels between baseline and 90 days was associated with all‐cause death (since 90 days to 1 year after index event) (adjusted HR, 1.99; 95% CI, 1.12–3.53; P =0.019) but not with poor functional outcome (adjusted OR, 1.08; 95% CI, 0.82–1.41). Conclusions Our study shows that high level and an increase in D‐dimer between baseline and 90 days are associated with poor outcomes in patients after ischemic stroke or transient ischemic attack. Nonstandard Abbreviations and Acronyms CNSRIII Third China National Stroke Registry mRS modified Rankin Scale NIHSS National Institutes of Health Stroke Scale TOAST Trial of Org 10172 in Acute Stroke Treatment Clinical Perspective What Is New? Baseline and 90‐day D‐dimer levels were associated with all‐cause death and poor functional outcome in a large population with ischemic stroke or transient ischemic attack. An increase in D‐dimer levels was associated with all‐cause death after ischemic stroke or transient ischemic attack. What Are the Clinical Implications? Dynamic measurements of D‐dimer levels might be helpful for identifying patient with stroke or transient ischemic attack at a higher risk of recurrent events. It is uncertain if patients with stroke or transient ischemic attack and an elevated D‐dimer may benefit from more aggressive antithrombotic or anticoagulant measures for secondary stroke prevention. Cerebrovascular disease is the leading cause of death and disability in China, with the majority of cases (69.6%–70.8%) involving ischemic stroke and transient ischemic attack (TIA). 1 , 2 Identifying potential risk factors of poor outcomes and developing targeted therapeutics are critical. In particular, we recently reported that lipid metabolism and inflammatory factors were associated with stroke outcomes. 3 , 4 , 5 D‐dimer, which is a fibrin degradation product, is a biomarker for coagulation and reflects increased thrombosis. 6 , 7 Although D‐dimer level has been clearly confirmed to be associated with death in the general population in the long term, 8 , 9 only a few studies assessed the association of D‐dimer with death 10 , 11 , 12</s -Abstract Truncated-

Abstract 5790: High Levels of Homocysteine and D-dimer Are Associated With Faster Functional Decline Among Men and Women With Lower Extremity Peripheral Arterial Disease

Relation of Thrombomodulin, TFPI and Plasma Antioxidants in Healthy Individuals and Patients with Coronary Heart Disease.

Relations Between Plasma Asymmetric Dimethylarginine (adma) and Risk Factors for Coronary Disease

Midlife Hemostasis Measures, 20-Year Cognitive Decline, and Incident Dementia

Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons

Femoral artery plaque characteristics, lower extremity collaterals, and mobility loss in peripheral artery disease.

Associations of Peripheral Artery Disease With Calf Skeletal Muscle Mitochondrial DNA Heteroplasmy

Association of multiple metabolic and cardiovascular markers with the risk of cognitive decline and mortality in adults with Alzheimer's disease and AD-related dementia or cognitive decline: a prospective cohort study

Body Fat Distribution, Cardiometabolic Traits, and Risk of Major Lower-Extremity Arterial Disease in Postmenopausal Women

Abstract P194: Proteomic Profiling of Pulmonary Function Decline and Cardiovascular Disease Risk in the Atherosclerosis Risk in Communities (ARIC) Study

D-Dimer In African Americans Whole Genome Sequence Analysis And Relationship To Cardiovascular Disease Risk In The Jackson Heart Study

D-Dimer in African Americans

Fatty acid binding protein 3 is associated with peripheral arterial disease

Novel Plasma Biomarkers Associated with Future Peripheral Atherosclerotic Disease and Abdominal Aortic Aneurysm—Insights from Contemporary Prospective Studies from the Malmö Diet and Cancer Study

Iron biomarkers predict peripheral artery disease in females: a cross-sectional analysis of HEIST-DiC and NHANES participants

Abstract P196: Metabolomic Associations With Cardiac Function and Incident Heart Failure in Multi-Ethnic Populations

Preliminary evidence that low ankle-brachial index is associated with reduced bilateral hip extensor strength and functional mobility in peripheral arterial disease

Association of Level and Increase in D-Dimer With All-Cause Death and Poor Functional Outcome After Ischemic Stroke or Transient Ischemic Attack.

Associations of Serum GDF-15 Levels with Physical Performance, Mobility Disability, Cognition, Cardiovascular Disease, and Mortality in Older Adults

High-risk plaque in the superficial femoral artery of people with peripheral artery disease: prevalence and associated clinical characteristics.

Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women